Impact of 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry

被引：0
|
作者：
Muller, Kristen [1 ]
Tafe, Laura [1 ]
Steinmetz, Heather [1 ]
Marotti, Jonathan [1 ]
机构：
[1] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
来源：
MODERN PATHOLOGY | 2015年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
215
引用
收藏
页码：57A / 57A
页数：1
相关论文
共 50 条
  • [41] Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
    Lei Guo
    Pei Yuan
    Jing Zhang
    Yun Ling
    Wenbin Li
    Bohui Zhao
    Jianming Ying
    Lixue Xuan
    Breast Cancer Research and Treatment, 2017, 166 : 77 - 84
  • [42] Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
    Guo, Lei
    Yuan, Pei
    Zhang, Jing
    Ling, Yun
    Li, Wenbin
    Zhao, Bohui
    Ying, Jianming
    Xuan, Lixue
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 77 - 84
  • [43] Impact of 2013 ASCO/CAP HER2 reporting guidelines in breast cancer: An assessment study from Indian oncology centre that primarily performs HER2 IHC testing with special emphasis on IHC equivocal category
    Pasricha, Sunil
    Gupta, Gurudutt
    Garg, Ritu
    Sharma, Anila
    Gandhi, Jatin S.
    Durga, Garima
    Kamboj, Meenakshi
    Grover, Shrruti
    Mehta, Anurag
    BREAST JOURNAL, 2018, 24 (04): : 468 - 472
  • [44] Impact of the new ASCO/CAP recommendations for the determination of HER2 by immunohistochemistry (IHC)
    Camacho, J.
    Temprana-Salvador, J.
    Diaz, S.
    Ramon y Cajal, S.
    Peg, V.
    VIRCHOWS ARCHIV, 2014, 465 : S106 - S106
  • [45] Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers
    Kamaljeet Singh
    Umadevi Tantravahi
    Michele M. Lomme
    Terese Pasquariello
    Margaret Steinhoff
    C. James Sung
    Breast Cancer Research and Treatment, 2016, 157 : 405 - 411
  • [46] Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers
    Singh, Kamaljeet
    Tantravahi, Umadevi
    Lomme, Michele M.
    Pasquariello, Terese
    Steinhoff, Margaret
    Sung, C. James
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (03) : 405 - 411
  • [47] Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
    Agersborg, Sally
    Mixon, Christopher
    Thanh Nguyen
    Aithal, Sramila
    Sudarsanam, Sucha
    Blocker, Forrest
    Weiss, Lawrence
    Gasparini, Robert
    Jiang, Shiping
    Chen, Wayne
    Hess, Gregory
    Albitar, Maher
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (02) : 321 - 328
  • [48] Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
    Agersborg, Sally
    Mixon, Christopher
    Thanh Nguyen
    Aithal, Sramila
    Blocker, Forrest
    Weiss, Lawrence
    Gasparini, Robert
    Jiang, Shiping
    Chen, Wayne
    Hess, Gregory
    Albitar, Maher
    CANCER RESEARCH, 2018, 78 (13)
  • [49] Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
    Sally Agersborg
    Christopher Mixon
    Thanh Nguyen
    Sramila Aithal
    Sucha Sudarsanam
    Forrest Blocker
    Lawrence Weiss
    Robert Gasparini
    Shiping Jiang
    Wayne Chen
    Gregory Hess
    Maher Albitar
    Breast Cancer Research and Treatment, 2018, 170 : 321 - 328
  • [50] Reassessment of HER2 Status in Invasive Micropapillary Carcinoma of the Breast - Recommendations for Improvement of 2023 ASCO/CAP Guideline on HER2 Testing
    Li, Y.
    Zhang, M.
    Yue, M.
    Yuan, X.
    Liu, C.
    Li, X.
    Liu, Y.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 104 - 105
12345